Examination of Fiscal Management and the Allocation of Care Act Resources US Department of Health and Human Services: Health REsources and Services Administration
INTRODUCTION
HIV/HCV Coinfection
HCV Treatment
Expanding Access to Treatment
Barriers and Key Issues
Conclusion
Resources
Hepatitis C Treatment
Growth Factors
Resources for Providers
Resources for Patients
References

Resources

Hepatitis C Treatment 

Roche (pegylated interferon alfa-2a [Pegasys] and Copegus [ribavirin])
For reimbursement information: 877-PEGASYS

Schering (pegylated interferon alfa-2b [PEG-Intron] and Rebetol [ribavirin])
The National Association of State and Territorial AIDS Directors and Schering-Plough have initiated the Commitment to Community Program. When HCV treatment is not included in a State ADAP formulary, the Commitment to Community Program will provide 1,500 slots for ADAP participants. This program is administrated via Schering’s Commitment to Care Program: (800) 521-7157.

Valeant (interferon alfacon-1[Procrit])
1-888 move fwd (1-888 668-3393)

 

 
 
<< Resources: General • Resources: Growth Factors >>